Key Drivers
- High gross margin
- Positive free cashflow
- Large accumulated losses
AIAI Summary
Aurinia's transition from a binary R&D bet to a margin‑positive, cash‑generating specialty pharma means the investment hinges on commercial execution—specifically whether LUPKYNIS prescriber adoption, persistence and payer coverage sustain current ~89% gross margins and the company converts FCF into durable EPS rather than one‑off buybacks. Monitor monthly prescription trends, 2026 guidance vs actual revenue, any FDA inquiries or label actions, and capital allocation between buybacks and aritinercept R&D as the immediate catalysts that will validate or unravel the current valuation upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Positive free cashflow
- •Large accumulated losses
AUPH shows strong unit economics and cash generation (very high gross margin, ~49% EBITDA margin, positive FCF and healthy liquidity) but suffers from distorted net income and equity metrics due to a large tax asset/negative tax expense and sizable accumulated losses that require scrutiny.
Price Behavior
Key Price Behavior Insights:
- •Modest downtrend
- •Tight range
- •Low volatility
AUPH is in a modest short-term downtrend over the last month (price $14.02 ≈2.6% below the last-month average ~$14.39) trading in a low-volatility range with support near $13.95 and resistance at $15.04, where a break above $15.04 would turn bullish and a close below $13.95 would reinforce bearish momentum.
Low 7–8% range over the last month limits sudden large moves
Sentiment & News
Key News Insights:
- •Revenue/EPS beat
- •Softer forward guidance
- •Transcript transparency
Aurinia delivered stronger-than-expected Q4 and FY revenue and EPS but shares fell after management issued cautious forward revenue targets that tempered investor enthusiasm.
The beat supports underlying business momentum, but muted 2026 targets will likely limit near-term upside in the stock until guidance is re-accelerated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings